Endoscopic sleeve gastroplasty using the novel Endomina device for morbidly obese patients

Treatment of obesity is necessary to reduce morbidity and mortality of itself, as well as secondary diseases such as diabetes and hypertension. Endoscopic sleeve gastroplasty (ESG) is a fairly new technique, first described in 2013 [1]. Since then, several methods have been used for the endoscopic creation of a stomach tube to reduce gastric volume [2, 3].

In January 2018 we treated two patients by ESG. Prior to this, they had both taken part successfully for 1 year in a nonsurgical multimodal treatment program for the morbidly obese, but thereafter had gained weight again. At the time of ESG, they had a body mass index (BMI) of 40.5 kg/m² and 37.7 kg/m², which along with their comorbidities fulfilled the criteria for bariatric surgery according to the German guidelines for surgery for obesity [4].

After informed consent had been obtained, ESG was performed with the patient under general anesthesia in our endoscopy unit, using a GIF-H190 gastroscope (Olympus, Tokyo, Japan), CO₂ insufflation, and the Endomina device (Endo Tools Therapeutics, Gosselies, Belgium) (▶ Fig.1), according to the method described by Huberty et al. [2]. Prior to treatment, each patient received a single shot of antibiotic (2 g ceftriaxone). Afterwards they received proton pump inhibitors for 2 weeks and antiemetics on demand.

The procedure was started in the greater curvature at the incisura with two stitches being placed, one above the other, and was then continued by stitching cranially in a row inside the stomach at the height of the second stitch to as near as possible to the gastroesophageal junction, leaving the fundus untouched. At the proximal end, we again placed two stitches one above the other. Based on the size of their stomachs, we used 12 stitches in one patient and 10 stitches in the other (▶ Fig.2, ▶ Fig.3; ▶ Video 1). The first procedure lasted 196 minutes and the second 99 minutes.

After the procedure, both patients felt a slight ache in the upper abdomen, but otherwise had no major complaints. For 2 days, they received liquids only and on
the third day started on a low-calorie diet. Within 3 months of undergoing ESG, one patient had lost 7 kg and the other 14 kg (BMI 38 kg/m² and 33.4 kg/m²). We conclude that ESG with the Endomina device is a feasible option for non-surgical anti-obesity treatment. The long-term effects of this treatment remain to be seen.

Endoscopy_UCTN_Code_TTT_1AO_2AN

Competing interests

None

The authors

Ingo Wallstabe¹, Nadine Oberaender², Arved Weimann², Ingo Schiefke¹

1 Department for Gastroenterology, Hepatology, Diabetology und Endocrinology, Klinikum St. Georg gGmbH, Leipzig, Germany
2 Department for General, Visceral- and Oncological Surgery with Unit for Clinical Nutrition, Klinikum St. Georg gGmbH, Leipzig, Germany

Corresponding author

Ingo Wallstabe, MD
Department of Gastroenterology and Hepatology, Klinikum St. Georg, Deltzscherr Str. 141, 04129 Leipzig, Germany
Fax: +49-341-9092673
ingo.wallstabe@endoskopieren.de

References


Bibliography

DOI https://doi.org/10.1055/a-0667-7696
Published online: 2018
Endoscopy
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X